A four-week, multicentre, double-blinded, randomised, active- and placebo-controlled, parallel-group trial investigating efficacy and safety of cannabidiol in acute, early-stage schizophrenic patients

Trial Profile

A four-week, multicentre, double-blinded, randomised, active- and placebo-controlled, parallel-group trial investigating efficacy and safety of cannabidiol in acute, early-stage schizophrenic patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Cannabidiol (Primary) ; Olanzapine
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 14 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
    • 30 Sep 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top